JAK3
JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Overview
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signalling events in both innate and adaptive immunity and plays a crucial role in haematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R.
CIViC holds 3 clinical evidence items and 0 assertions across 8 variants, naming Atezolizumab and Tofacitinib. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes clinical 0.96, affected pathway 0.61, literature 0.95, genetic association 0.18, somatic mutation 0.97, animal model 0.53). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Acute Lymphoblastic Leukaemia.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
- 1 · What it is
JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
- 2 · What goes wrong in cancer
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation.
- 3 · How drugs use it
No product in this corpus aims at JAK3 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:6193 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P52333 (protein name, function text, keywords and locations (REST API)); CIViC gene JAK3 (3 evidence items, 0 assertions, 8 variants; diseases: Lung Adenocarcinoma, T-cell Acute Lymphoblastic Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000105639 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: colorectal cancer 0.52, acute lymphoblastic leukaemia 0.62, non-Hodgkin lymphoma 0.65, skin cancer 0.58, myeloproliferative neoplasm 0.73, acquired polycythemia vera 0.55 (GraphQL API, CC0)); IntOGen JAK3 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signalling events in both innate and adaptive immunity and plays a crucial role in haematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. Location: Endomembrane system; Cytoplasm (UniProt). Locus 19p13.11 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.73 with myeloproliferative neoplasm (MONDO_0020076)
- Leukaemia: Open Targets association 0.67 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.65 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.58 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.55 with lung cancer (MONDO_0008903)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 3 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: T-cell Acute Lymphoblastic Leukaemia.
Latest papers
topQuery for this target: (TITLE:"JAK3" OR ABSTRACT:"JAK3" OR TITLE:"Janus kinase 3" OR ABSTRACT:"Janus kinase 3" OR TITLE:"Tyrosine-protein kinase JAK3" OR ABSTRACT:"Tyrosine-protein kinase JAK3" OR TITLE:"L-JAK" OR ABSTRACT:"L-JAK" OR TITLE:"JAK3_HUMAN" OR ABSTRACT:"JAK3_HUMAN" OR TITLE:"JAK-3" OR ABSTRACT:"JAK-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JAK3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetBCL6
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetZRSR2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetBIRC3
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetFANCA
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetPAX5
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPOLD1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetIL7R
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTBL1XR1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).